The market is driven by high incidence of cancer and arthritis as well as the development of extended release formulations and drug combinations.
Opioids continue to be a mainstay in acute and chronic therapy. NSAIDs/Cox-2 inhibitors, the alternative, have cardiovascular and renal side-effects and the older NSAIDs have severe gastrointestinal side effects. However, sales of opioids are hampered by weak pipelines and generic competition.
Read the Research and Markets release on opioids.
Related Articles on Opioids:
Army Grants $5.6M to Research Sublingual Opioid for Pain
6 Steps Pain Physicians Can Take to Curtail Misuse of Opioids
Opioid Pain Medications Drive “Epidemic” of Unintentional Drug Overdose Deaths
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.